NeoPhore Secures £6M Series B Funding for Cancer Innovation
In a bold move that's set to reshape the landscape of cancer treatment, NeoPhore, a pioneering small molecule neoantigen immuno-oncology firm based in Cambridge, UK, has successfully raised an impressive £6M in an extension of its Series B funding, bringing the total funding to a remarkable £21.5M. This influx of capital, backed by key investors like CRT Pioneer Fund, Claris Ventures, 2Invest, 3B Future Health Fund, and Astellas Venture Management, marks a significant milestone in the company's quest to revolutionize cancer therapies through innovative immuno-oncology approaches.
With ambitions to expedite its expanding pipeline of drugs, NeoPhore is strategically channeling these funds towards the initiation of IND-enabling studies scheduled for 2024. Under the visionary leadership of CEO Matthew Baker, the company is dedicated to harnessing the potential of cancer neoantigens, which can trigger the body’s immune system to combat tumors more effectively. By tapping into the DNA mismatch repair (MMR) pathway, NeoPhore is poised to develop next-generation therapeutics that not only generate neoantigens but also enhance immune responses against various forms of cancer—an approach that carries the promise of better clinical outcomes for patients.
NeoPhore's rapid progress has already demonstrated impressive results; by January 2022, the company had achieved all its investment-related scientific milestones ahead of schedule. Its partnerships with esteemed institutions, such as St George’s, University of London, and Memorial Sloan Kettering Cancer Center (MSK), have set the stage for advancing research on its proprietary DNA mismatch repair inhibitor (MMRi) compounds. These collaborations are critical as NeoPhore continues to validate and optimize its innovative therapies, positioning it as a promising contender in the competitive landscape of cancer investment. For startup founders and investors keen on the intersection of technology and healthcare, keeping an eye on NeoPhore's journey is essential—this company is on the brink of something transformative in the realm of cancer treatment.
Key Terms Explained
- Series B funding
- The second round of funding for a business through investment, including private equity investors and venture capitalists, following a successful round A.
- IND-enabling studies
- These are preclinical studies that must be performed before an Investigational New Drug (IND) application can be filed with the FDA. They typically include pharmacology, toxicology, pharmacokinetics, and other studies to ensure safety of human trials.
- DNA mismatch repair (MMR) pathway
- A system within the cell for recognizing and repairing erroneous insertion, deletion and mis-incorporation of bases that can arise during DNA replication and recombination, as well as repairing some forms of DNA damage.
Frequently Asked Questions
- How much funding has NeoPhore raised for its immuno-oncology research?-NeoPhore has raised a total of £21.5M in funding for its immuno-oncology research.
- Who are some investors that have backed NeoPhore's cancer research?+
- What is the importance of the funding NeoPhore has raised?+
- What is the primary focus of NeoPhore's research in cancer treatment?+
- What achievements has NeoPhore made in their research field?+
They've invested in NeoPhore
Get to know these Biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 CRT Pioneer Fund( ) Oxford  | ||||
 Claris Ventures( ) Turin, Italy  | ||||
 3B Future Health Fund( ) Luxembourg, Luxembourg | ||||
 Astellas Venture Management( ) Astellas Venture Management (AVM) is a wholly-owned venture capital organisation... Brisbane, Australia | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK